QARS1 (glutaminyl-tRNA synthetase 1) is a member of the aminoacyl-tRNA synthetase (ARS) family, enzymes essential for protein synthesis. It catalyzes the attachment of glutamine to its cognate tRNA, ensuring the accurate translation of mRNA into proteins. Beyond its canonical role, QARS1 has been implicated in non-canonical functions, including immune signaling and cellular stress responses. Dysregulation of QARS1 is linked to neurological disorders, such as progressive microcephaly and cortical atrophy, often caused by recessive mutations in the QARS1 gene. Antibodies targeting QARS1 are critical tools in studying its expression, localization, and molecular interactions. They enable researchers to investigate its role in disease pathogenesis, particularly in rare genetic conditions, and to explore potential therapeutic strategies. Commercial QARS1 antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Recent studies also highlight its potential involvement in cancer biology, where altered QARS1 expression may influence tumor progression. However, challenges remain in distinguishing QARS1-specific signals from cross-reactivity with other ARS family members, emphasizing the need for rigorous antibody validation. Overall, QARS1 antibodies serve as indispensable reagents in both basic research and clinical diagnostics, bridging gaps in understanding tRNA synthetase biology and human disease mechanisms.